RxSight (RXST) Competitors $13.20 +0.06 (+0.45%) Closing price 07/3/2025 03:35 PM EasternExtended Trading$13.30 +0.10 (+0.76%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, AORT, and LQDAShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), Artivion (AORT), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors NovoCure LeMaitre Vascular National Vision Enovis CONMED Tandem Diabetes Care SS Innovations International Cadre Artivion Liquidia Technologies RxSight (NASDAQ:RXST) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Is RXST or NVCR more profitable? RxSight has a net margin of -17.90% compared to NovoCure's net margin of -26.41%. RxSight's return on equity of -9.54% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets RxSight-17.90% -9.54% -8.51% NovoCure -26.41%-45.46%-13.34% Do insiders & institutionals hold more shares of RXST or NVCR? 78.8% of RxSight shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 9.6% of RxSight shares are owned by insiders. Comparatively, 5.5% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility and risk, RXST or NVCR? RxSight has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Does the media refer more to RXST or NVCR? In the previous week, NovoCure had 6 more articles in the media than RxSight. MarketBeat recorded 7 mentions for NovoCure and 1 mentions for RxSight. RxSight's average media sentiment score of 0.50 beat NovoCure's score of 0.39 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate RXST or NVCR? RxSight currently has a consensus target price of $37.90, suggesting a potential upside of 187.14%. NovoCure has a consensus target price of $32.83, suggesting a potential upside of 85.45%. Given RxSight's higher possible upside, analysts plainly believe RxSight is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.30NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has better valuation & earnings, RXST or NVCR? RxSight has higher earnings, but lower revenue than NovoCure. RxSight is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRxSight$139.93M3.83-$27.45M-$0.67-19.70NovoCure$605.22M3.26-$168.63M-$1.51-11.73 SummaryRxSight beats NovoCure on 11 of the 16 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$530.31M$6.86B$5.53B$9.05BDividend YieldN/A1.21%5.24%4.03%P/E Ratio-19.7026.1527.5220.22Price / Sales3.8399.70421.02118.64Price / CashN/A21.0936.8958.07Price / Book1.894.748.045.67Net Income-$27.45M$173.18M$3.18B$249.13M7 Day Performance4.18%1.33%2.90%3.28%1 Month Performance-11.53%0.16%3.70%5.55%1 Year Performance-76.82%23.71%36.15%21.12% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight1.7709 of 5 stars$13.20+0.4%$37.90+187.1%-76.8%$530.31M$139.93M-19.70220News CoverageNVCRNovoCure3.6878 of 5 stars$16.61-0.5%$32.83+97.7%+4.9%$1.86B$605.22M-11.001,488LMATLeMaitre Vascular2.7158 of 5 stars$83.38+2.0%$97.83+17.3%+3.8%$1.85B$219.86M42.11490Positive NewsEYENational Vision2.652 of 5 stars$22.69-0.8%$18.67-17.7%+92.2%$1.81B$1.82B-68.7613,411Positive NewsENOVEnovis3.549 of 5 stars$30.01-0.3%$58.00+93.3%-24.3%$1.72B$2.11B-2.157,367Positive NewsCNMDCONMED4.6557 of 5 stars$51.72-0.9%$62.20+20.3%-19.5%$1.61B$1.31B13.613,900Positive NewsTNDMTandem Diabetes Care4.2181 of 5 stars$20.22flat$33.43+65.3%-57.1%$1.35B$940.20M-7.272,650Positive NewsSSIISS Innovations InternationalN/A$5.65-18.4%N/AN/A$1.34B$22.13M0.004Positive NewsCDRECadre3.6812 of 5 stars$32.76-0.3%$37.50+14.5%-5.3%$1.34B$567.56M34.482,284AORTArtivion2.4992 of 5 stars$30.84+1.9%$32.00+3.8%+18.8%$1.29B$388.54M-61.671,600LQDALiquidia Technologies3.2403 of 5 stars$13.26+0.7%$26.89+102.8%+2.4%$1.13B$14M-8.3950Positive News Related Companies and Tools Related Companies NovoCure Alternatives LeMaitre Vascular Alternatives National Vision Alternatives Enovis Alternatives CONMED Alternatives Tandem Diabetes Care Alternatives SS Innovations International Alternatives Cadre Alternatives Artivion Alternatives Liquidia Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
